Last reviewed · How we verify
Omecamtiv Mecarbil (OM)
Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole.
Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole. Used for Heart failure with reduced ejection fraction (HFrEF), Acute heart failure.
At a glance
| Generic name | Omecamtiv Mecarbil (OM) |
|---|---|
| Also known as | AMG 423 |
| Sponsor | Cytokinetics |
| Drug class | Cardiac myosin activator |
| Target | Cardiac myosin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The drug binds to cardiac myosin and increases the probability that myosin heads will enter the force-generating state, thereby enhancing cardiac contractility without increasing heart rate or oxygen consumption proportionally. This mechanism is distinct from traditional inotropes and aims to improve cardiac output in heart failure patients by making the existing heart muscle work more efficiently.
Approved indications
- Heart failure with reduced ejection fraction (HFrEF)
- Acute heart failure
Common side effects
- Ventricular arrhythmias
- Increased troponin levels
- Dizziness
- Headache
Key clinical trials
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction (PHASE3)
- Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults (PHASE1)
- Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction (PHASE3)
- COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (PHASE2)
- Omecamtiv Mecarbil Post-trial Access Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omecamtiv Mecarbil (OM) CI brief — competitive landscape report
- Omecamtiv Mecarbil (OM) updates RSS · CI watch RSS
- Cytokinetics portfolio CI